{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:51:15Z","timestamp":1790844675887,"version":"4.1.0"},"reference-count":47,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.2217\/fon-2021-1387","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T10:23:41Z","timestamp":1643624621000},"page":"1089-1101","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Multi-Country Study of\n            <i>BRCA1\/2<\/i>\n            Mutation Testing Among Adult Women with HER2-Negative Advanced Breast Cancer"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2781-2178","authenticated-orcid":false,"given":"Michael P","family":"Lux","sequence":"first","affiliation":[{"name":"Kooperatives Brustzentrum Paderborn,\rFrauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, Frauen- und Kinderklinik St. Louise, St. Vincenz-Kliniken,\rHusener Strasse 81,Paderborn33098,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-7587","authenticated-orcid":false,"given":"Katie","family":"Lewis","sequence":"additional","affiliation":[{"name":"Oncology Franchise,\rAdelphi Real World,\rCheshire,SK10 5JB,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-002X","authenticated-orcid":false,"given":"Alex","family":"Rider","sequence":"additional","affiliation":[{"name":"Oncology Franchise,\rAdelphi Real World,\rCheshire,SK10 5JB,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-9661","authenticated-orcid":false,"given":"Alexander","family":"Niyazov","sequence":"additional","affiliation":[{"name":"Patient Health Impact,\rPfizer Inc.,\rNew York,NY10071,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.2741\/4230"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29041"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13053-015-0038-x"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy192"},{"key":"e_1_3_6_7_1","unstructured":"National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer (version 5)www.nccn.org\/professionals\/physician_gls\/pdf\/breast_blocks.pdf"},{"key":"e_1_3_6_8_1","first-page":"CD003374","article-title":"Platinum-containing regimens for metastatic breast cancer","volume":"6","author":"Egger SJ","year":"2017","unstructured":"Egger SJ , WillsonML, MorganJet al. Platinum-containing regimens for metastatic breast cancer. Cochrane Database Syst. Rev.6, CD003374 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_3_6_11_1","unstructured":"European Medicines Agency . Assessment report: Talzenna [Procedure No. EMEA\/H\/C\/004674\/0000](2019).www.ema.europa.eu\/en\/documents\/assessment-report\/talzenna-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_6_12_1","unstructured":"European Medicines Agency TALZENNA\u00ae (talazoparib) Summary of Product Characteristics. www.ema.europa.eu\/en\/documents\/product-information\/talzenna-epar-product-information_en.pdf"},{"key":"e_1_3_6_13_1","unstructured":"Pfizer . TALZENNA\u00ae (talazoparib) prescribing information(2018).http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11046"},{"key":"e_1_3_6_14_1","unstructured":"European Medicines Agency . Assessment report: Lynparza [Procedure No. EMEA\/H\/C\/003726\/II\/0020](2019).www.ema.europa.eu\/en\/documents\/variation-report\/lynparza-h-c-3726-ii-0020-epar-assessment-report-variation_en.pdf"},{"key":"e_1_3_6_15_1","unstructured":"Electronic Medicines Compendium (UK) . LYNPARZA\u00ae (olaparib) Summary of Product Characteristics(2022). www.medicines.org.uk\/emc\/product\/9204\/smpc"},{"key":"e_1_3_6_16_1","unstructured":"AstraZeneca . LYNPARZA\u00ae (olaparib) prescribing information(2014).www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf#page=1"},{"key":"e_1_3_6_17_1","unstructured":"National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): genetic\/familial high-risk assessment: breast ovarian and pancreatic (version 1). www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501000"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw327"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS17-PD1-02"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S206949"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01854"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.6314"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0867-x"},{"issue":"2","key":"e_1_3_6_25_1","first-page":"S62","article-title":"Germline BRCA1\/2 (gBRCA1\/2) testing patterns among oncologists (ONC) treating HER2- advanced breast cancer (ABC): results from a multi-country real-world study","volume":"31","author":"Mahtani RL","year":"2020","unstructured":"Mahtani RL , NiyazovA, LewisKet al. Germline BRCA1\/2 (gBRCA1\/2) testing patterns among oncologists (ONC) treating HER2- advanced breast cancer (ABC): results from a multi-country real-world study. Ann. Oncol.31(Suppl. 2), S62\u2013S82 (2020).","journal-title":"Ann. Oncol."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv298"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt284"},{"key":"e_1_3_6_28_1","unstructured":"American Society of Breast Surgeons . Consensus Guideline on Genetic Testing for Hereditary Breast Cancer (2019). www.breastsurgeons.org\/docs\/statements\/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00299"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S120101"},{"key":"e_1_3_6_33_1","unstructured":"European Pharmaceutical Market Research Association . Code of Conduct(2021).www.ephmra.org\/standards\/code-of-conduct\/"},{"key":"e_1_3_6_34_1","unstructured":"US Department of Health & Human Services . Summary of the HIPAA Privacy Rule. www.hhs.gov\/sites\/default\/files\/privacysummary.pdf"},{"key":"e_1_3_6_35_1","unstructured":"Office of the National Coordinator for Health Information Technology . Health Information Technology Act(2009). www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1159\/000505957"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.1414"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31841"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030525"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S189627"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29010"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3323"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092415"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100235"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0712-x"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu385"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw544"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1113"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-1387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:25Z","timestamp":1719125005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-1387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.2217\/fon-2021-1387"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-1387","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}